Subacute thyroiditis: clinical significance of diffuse 18-fluorodeoxyglucose uptake. Case report

Cover Page

Cite item

Full Text

Abstract

Background. Subacute thyroiditis is a rare inflammatory thyroid disease presumably associated with viral infection, including COVID-19. It accounts for about 5% of all thyroid diseases.

Materials and methods. A clinical case of de Quervain's subacute thyroiditis in a patient with diffuse hypermetabolic 18-fluorodeoxyglucose uptake by the thyroid gland is presented.

Results. A 61-year-old patient with no history of thyroid disorders 3 weeks after COVID-19 experienced fever in the evenings (37.8–39.8°C). He had moderate pain in the thyroid gland with radiation to the jaw, severe weakness, hand tremors, shivers, 12 kg weight loss, and sweating. These symptoms lasted for 3 weeks. Physical examination showed an enlarged thyroid gland, dense and extremely tender, especially its left lobe. Ultrasound showed an enlarged thyroid gland with a heterogeneous structure and large hypoechoic areas in both lobes up to 4×7 mm with fuzzy contour. Color Doppler imaging revealed reduced blood flow. Combined positron-emission and X-ray computed tomography with 18-fluorodeoxyglucose showed an increased diffuse uptake of the radiopharmaceutical in the thyroid gland and enlargement of its lobes, SUVmax 10.55. Blood thyroid-stimulating hormone is low, free triiodothyronine and thyroxine are high, and ferritin concentration is markedly increased, consistent with thyrotoxicosis. A fine-needle aspiration biopsy was performed. Cytology confirmed de Quervain's subacute thyroiditis. Glucocorticoids and nonsteroidal anti-inflammatory drugs were administered. Four weeks after the treatment, the clinical manifestations resolved. The patient was assessed in 6 months. Ultrasound showed a thyroid gland of regular size with smooth contours; color Doppler mapping revealed normal blood flow. Thyroid-stimulating hormone, triiodothyronine, and thyroxine were within reference ranges.

Conclusion. The SARS-CoV-2 virus can be regarded as the cause of subacute thyroiditis. Combined positron-emission and X-ray computed tomography with 18-fluorodeoxyglucose showed diffuse intensive radiopharmaceutical uptake in the thyroid gland. Cytology is the basis for differential diagnostics. Glucocorticoids and nonsteroidal anti-inflammatory drugs are the first-choice agents.

About the authors

Nikolai A. Ognerubov

Derzhavin Tambov State University

Author for correspondence.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247

D. Sci. (Med.), Cand. Sci. (Law), Prof.

Russian Federation, Tambov

Tatiana S. Antipova

PET-Technology

Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4165-8397

doctor

Russian Federation, Tambov

Elena E. Palkina

Tambov Regional Oncological Clinical Dispensary

Email: palkina68@mail.ru

cytologist

Russian Federation, Tambov

References

  1. Braga M, Brito JP, Lewiński A, Płaczkiewicz-Jankowska E. Subacute Painful Thyroiditis (de Quervain Thyroiditis). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Available at: https://empendium.com/mcmtextbook/chapter/B31.II.9.3.3. Accessed: 02.07.2023.
  2. Xu C, Jiang R, Liu JY. Emerging trends and hot spots in subacute thyroiditis research from 2001 to 2022: A bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1144465. doi: 10.3389/fendo.2023.1144465
  3. Sözen M, Topaloğlu Ö, Çetinarslan B, et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum Vaccin Immunother. 2021;17(12):5120-5. doi: 10.1080/21645515.2021.2013083
  4. Stasiak M, Michalak R, Stasiak B, Lewinski A. Clinical characteristics of subacute thyroiditis is different than it used to be – current state based on 15 years own material. Neuro Endocrinol Lett. 2019;39(7):489-95.
  5. Ramineni P, Kamath SP, Joshi J, Rao S. Subacute thyroiditis with airway compromise in a 5-year-old boy. BMJ Case Rep. 2020;13(11):e236909. doi: 10.1136/bcr-2020-236909
  6. Bostan H, Sencar ME, Calapkulu M, et al. Impact of the COVID-19 pandemic on the incidence, seasonal distribution, and characteristics of subacute thyroiditis. Endocrine. 2022;79(2):323-30. doi: 10.1007/s12020-022-03197-3
  7. Ahn HY, Choi HS, Ha S, Cho SW. Incidence of subacute thyroiditis during the COVID-19 pandemic in south Korea using the national health insurance service database. Thyroid. 2022;32(11):1299-306. doi: 10.1089/thy.2022.0363
  8. Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88:2100-5.
  9. Hennessey Jv. Subacute Thyroiditis. [Updated 2018 Jun 12]. In: Endotext. Eds. KR Feingold, B Anawalt, MR Blackman, et al. South Dartmouth (MA): MDText.com, Inc.; 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279084/ Accessed: 12.02.2023.
  10. Yeo SH, Lee SK, Hwang I, Ahn EJ. Subacute thyroiditis presenting as a focal lesion on [18F] fluorodeoxyglucose whole-body positron-emission tomography/CT. Am J Neuroradiol. 2011;32(4):E58-60. doi: 10.3174/ajnr.A2017
  11. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007;48(6):896-901. doi: 10.2967/jnumed.106.039024
  12. Quervain F. Über acute, nichteitrige thyroiditis. Arch Für Klin Chir. 1902;67:706-14.
  13. Mangaraj S. Subacute thyroiditis complicating dengue fever – case report and brief review of literature. Trop Doct. 2021;51(2):254-6. doi: 10.1177/0049475520977821
  14. Zornitzki T, Mildiner S, Schiller T, et al. Subacute thyroiditis-still a diagnostic challenge: Data from an observational study. Int J Environ Res Public Health. 2022;19(15):9388. doi: 10.3390/ijerph19159388
  15. Volpe The management of subacute (DeQuervain's) thyroiditis. Thyroid. 1993;3(3):253-5.
  16. Xu C, Jiang R, Liu JY. Emerging trends and hot spots in subacute thyroiditis research from 2001 to 2022: A bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1144465. doi: 10.3389/fendo.2023.1144465
  17. Kong M, La Porte S. Case Report: De Quervain's Thyroiditis as a Long-Term Sequelae Complication to SARS-CoV-2 Infection. Case Rep Acute Med. 2021;4(2):64-70. doi: 10.1159/000517705
  18. Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-COV-2 infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276. doi: 10.1210/clinem/dgaa276
  19. Pipitone G, Rindi LV, Petrosillo N, et al. Vaccine-Induced Subacute Thyroiditis (De Quervain's) after mRNA Vaccine against SARS-CoV-2: A Case Report and Systematic Review. Infect Dis Rep. 2022;14(1):142-54. doi: 10.3390/idr14010018
  20. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-55. doi: 10.1056/NEJMra021194
  21. Park JY, Choi W, Hong AR, et al. Early thyroid volume reduction in subacute thyroiditis can be a potential indicator for hypothyroidism. Front Endocrinol (Lausanne). 2022;13:888018. doi: 10.3389/fendo.2022.888018
  22. Stasiak M, Michalak R, Stasiak B, Lewiński A. Time-lag between symptom onset and diagnosis of subacute thyroiditis – how to avoid the delay of diagnosis and unnecessary overuse of antibiotics. Horm Metab Res. 2020;52(1):32-8. doi: 10.1055/a-1033-7524
  23. Park SY, Kim EK, Kim MJ, et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol. 2006;7:229-34.
  24. Saydam BO, Adiyaman SC, Demir T, et al. The use of low dose prednisolone in patients with subacute thyroiditis and its effect on impaired life and sleep quality. Acta Endocrinol (Buchar). 2022;18(1):64-73. doi: 10.4183/aeb.2022.64
  25. Arao T, Okada Y, Torimoto K, et al. Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis. J UOEH. 2015;37:103-10.
  26. Iitaka M, Momotani N, Ishii J, et al. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab. 1996;81:466-9.
  27. Huo J, Chen C, Gao D, et al. Ultrasound-guided capsular thyroid injection therapy with dexamethasone and lidocaine mixture for subacute thyroiditis: A single-center study. J Ultrasound Med. 2022;42(3):613-21. doi: 10.1002/jum.16054

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1

Download (148KB)
3. Fig. 2

Download (164KB)

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies